translation agency

United Press International
Harmless virus may hinder AIDS
Charles Choi in New York
October 31, 2001
Research from the National Institutes of Health finds a common and apparently harmless virus appears to significantly hinder early stages of HIV infection in laboratory grown human tissue.

"Future research could lead to new drugs that can better help the immune system to fend off HIV, and may even lead to new strategies for designing a vaccine against HIV," said Duane Alexander, director of the National Institute of Child Health and Human Development, the organization which led the research.

Scientists, however, strongly recommend against AIDS patients running out to get infected with the apparently helpful germ -- human herpesvirus 6 or HHV-6 -- especially as it may enhance human immunodeficiency virus growth in the later stages of the disease.

"Before these approaches could be developed and tested, any attempts to use HHV-6 to slow down HIV infection are risky and premature," cautioned lead researcher Leonid Margolis.

Human herpesvirus 6 is common throughout the world. It does not seem to cause any illness in adults, although infants infected with the germ may develop a mild rash that disappears within several days.

Margolis and his colleagues worked with lab-grown human tonsil tissue they infected with both HIV and HHV-6. They found human herpesvirus 6 dramatically suppressed the growth of the HIV variants that dominate the early stages of infection.

Both early and late stage variants of HIV bind to molecules called receptors that poke out of the surfaces of cell membranes. Molecules on the surface of HIV bind to immune cell receptors much as keys fit in locks, allowing the virus to fuse with cells and infect them.

Early stage versions of HIV bind to a receptor known as CCR5. People infected with these germs may not show any outward sign of disease for a long period. Late stage variants of HIV, however, are associated with the rapid decline of the immune system. They bind to a different receptor, CXCR4.

The scientists discovered human herpesvirus 6 dramatically slows down the growth of early stage HIV by triggering the release of large amounts of a biochemical called RANTES. This molecule apparently blocks the CCR5 receptor, essentially acting like a plug so HIV cannot come in.

On the other hand, the late-stage HIV variants that use CXCR4 appeared to reproduce slightly more rapidly in the presence of HHV-6. This increase in growth rate did not, however, approach statistical significance.

Recent studies suggest a number of infections appear to hinder HIV, among them the apparently harmless GBV-C virus and the microbes that cause the potentially lethal illness scrub typhus. Jack Stapleton, senior researcher behind the GBV-C findings, said the technique of using living human tissue represented a major advance, as it allowed Margolis' team to identify the mechanism behind human herpesvirus 6's anti-HIV effect.

"If the trigger for that mechanism can be identified, the next step would be try to mimic that effect to create a drug," Stapleton said in an interview with United Press International. "In theory, the ability of HIV to resist a drug that acts on the cell may be lower than the ability of HIV to resist drugs that act on the virus as current types of HIV medicine do."

www.aegis.org